











## **Prior Authorization Request Administrative Information**

Member Information				
Last name First name MI				
Member ID Date of birth				
Sex assigned at birth Female Male "X" or Intersex				
Current gender  Female  Male  Transgender male  Transgender female  Other				
Place of residence				
Race/ethnicity Preferred spoken language Preferred written language				
MassHealth does not exclude people or treat them differently because of race, color, national origin, age,				
disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).				
Plan Contact Information				
Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to				
the Plan's contact information below.				
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan				
☐ MassHealth Drug Utilization Review Program				
Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318				
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)				
Fallon Health				
Online Prior Authorization: go.covermymeds.com/OptumRx				
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum				
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033				
Health New England				
Online Prior Authorization: go.covermymeds.com/OptumRx				
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545				
☐ Mass General Brigham Health Plan				
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx				
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org				
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555				
☐ Tufts Health Plan				
Online Prior Authorization: point32health.promptpa.com				
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985				
☐ WellSense Health Plan				
Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations				
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822				

## **Anticonvulsant Prior Authorization Request**

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about anticonvulsants and the **Pediatric Behavioral Health Medication Initiative**, including PA requirements, a complete list of all behavioral health medications, and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**. The related PA form is available at: **Pediatric Behavioral Health Medication Initiative PA Request Form**.

Medication information				
Medication requested (Check one or a	all that apply.)			
Medication requested (Check one or all that apply.)  Aptiom (eslicarbazepine)  Briviact (brivaracetam solution, tablet)  Diacomit (stiripentol)  diazepam rectal gel > 5 kits (10 syringes)/month  Elepsia XR (levetiracetam extended-release)  Epidiolex (cannabidiol)  Eprontia (topiramate solution)  everolimus 2.5 mg, 5 mg, 7.5 mg, 10 mg  everolimus tablets for oral suspension  Fintepla (fenfluramine)  Fycompa (perampanel)  gabapentin >3600 mg/day  Lamictal XR starter kit, lamotrigine extended-release  lamotrigine orally disintegrating tablet (ODT),  ODT starter kit		<ul> <li>Motpoly XR (lacosamide extended-release capsule)</li> <li>Nayzilam (midazolam nasal spray) &gt;10 units/month</li> <li>Oxtellar XR (oxcarbazepine extended-release)</li> <li>pregabalin</li> <li>rufinamide</li> <li>Spritam (levetiracetam tablet for oral suspension)</li> <li>Sympazan (clobazam film)</li> <li>tiagabine</li> <li>topiramate extended-release capsule [Trokendi XR]</li> <li>Valtoco (diazepam nasal spray) &gt;10 units/month</li> <li>vigabatrin</li> <li>Xcopri (cenobamate)</li> <li>Zonisade (zonisamide suspension)</li> <li>Ztalmy (ganaxolone)</li> <li>Other*</li> </ul>		
Dose, frequency, and duration of me	dication reques	ted		
Drug NDC (if known) or service code				
* If request is for a non-preferred brand copies of medical records and/or office product).				
Indication (Check all that apply or inclu	ide ICD-10 code,	, if applicable.)		
<ul> <li>□ Bipolar disorder</li> <li>□ Cyclin-dependent kinase-like 5         (CDKL5) deficiency disorder         (CDD) (provide documentation         of genetic testing)</li> <li>□ Diabetic peripheral neuropathy</li> <li>□ Dravet syndrome</li> </ul>	Type Epilepsy as		<ul> <li>☐ Lennox-Gastaut syndrome</li> <li>☐ Migraine prophylaxis</li> <li>☐ Pain associated with trigeminal neuralgia</li> <li>☐ Postherpetic neuralgia</li> <li>☐ Other</li> </ul>	

PA-18 (Rev. 05/24) over

Please list all other medications currentle	y prescribed for the mem	ber for this indication.	
Please indicate prescriber specialty belo	ow.		
☐ Neurology ☐ Psychiatry ☐ Othe			
If prescriber is not a specialist, pleas For mid-level practitioners (e.g., nurse p			e and specialty
of the collaborating physician, if applicat	• • •	sistanto), piodeo provido trio marrio	
	" " O 🗆 V		
Is this member a referral candidate for c If yes, MassHealth will offer care coordin			itional
behavioral health services would be ber		mbor. I lodge describe which dad	tional
Section I. Please complete for all	requests as needed.		
Please provide the following information	-	*	
1. Drug	Dates of Use	Outcome	
2. Drug	Dates of Use	Outcome	
3. Drug	Dates of Use	Outcome	
4. Drug	Dates of Use	Outcome	
*Attach a letter with additional information	on regarding medication ti	rials as applicable.	
Section II. Please also complete for	or requests for Elepsia	a XR, Eprontia, Lamictal XR s	starter kit.
•		olet starter kit, Motpoly XR, C	
	•	le [Trokendi XR], and Zonisa	
Please provide medical necessity for the that is available without prior authorization	•	•	•
		<u>'</u>	
	quests for gabapentin	> 3600 mg/day and pregabal	in > 600
mg/day.  Please provide clinical rationale for exce	eding the maximum daily	dose limit	
Tiedes provide difficult rationals for executive	yearing the maximum daily	4000 mmm	
Costion IV Diseas commists for ma	waste for Discounit		
Section IV. Please complete for red  1. Has the member experienced an ina	-	erse reaction to other anticonvuls	ants?
☐ Yes. Please complete Section I a	bove.		
☐ No. Explain why other anticonvul	sants have not been tried	·	

2.	Will the	requested agent be used in combination with clobazam?   Yellow	es 🗌 No
Sect	tion V.	For requests for Epidiolex, please attach medical re	cords supporting the diagnosis.
1.	Does the ☐ Yes. Has the ☐ Yes.	Please complete for requests for lamotrigine ODT.  ne member have a medical condition in which they are not able  Please describe.  ne member experienced an inadequate response or adverse reactive.  Please describe trial below.  Dates of Use	No
		Explain why lamotrigine dispersible tablets have not been tried.	
1.	Is the dia	Please complete for requests for diazepam rectal ge units/30 days), and Valtoco (> 10 units/30 days).  liagnosis for as needed (intermittent) treatment of acute seizure er's usual seizure pattern?   Yes  No describe the medical necessity for use over quantity limits.	
		I. Concomitant gabapentin and pregabalin. Complete to request will result in prescription of concomitant gastument complete treatment plan.	•
		ntin dose/frequency	Indication
		alin dose/frequency	Indication
	Other(s) ase docu	ument clinical rationale for concomitant use of gabapentin and	pregabalin for this member.
		ument monotherapy trials (include dose/frequency, dates/durat and pregabalin.*	ion of use, and outcome) with
	the reque Yes. Plea	ember experienced an inadequate response or adverse reaction uested indication(s)? ease complete Section I above. Plain why other alternative agents have not been tried.	n to at least two other alternative agents
- 1			

<b>Se</b> 1.	ction IX. Please complete and provide documentation for exceptions to Step Therapy.  Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse
	reaction in, or physical or mental harm to the member?   Yes No
	If yes, briefly describe details of contraindication, adverse reaction, or harm.
2.	clinical characteristics of the member and the known characteristics of the alternative drug regimen?  ☐ Yes ☐ No
	If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.
3.	Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
	☐ Yes ☐ No
	If yes, please provide details for the previous trial.
	Drug name Dates/duration of use
	Did the member experience any of the following?   Adverse reaction   Inadequate response
	Briefly describe details of adverse reaction or inadequate response.
4.	Is the member stable on the requested prescription drug prescribed by the health care provider, and switching
	drugs will likely cause an adverse reaction in or physical or mental harm to the member?
	☐ Yes. Please provide details. ☐ No
*	Attach a letter with additional information regarding medication trials as applicable.
Μa	ssHealth Pediatric Behavioral Health Medication Initiative
	Please fill out all the sections below, as applicable, for pediatric members only. You may also use the
	ediatric Behavioral Health Medication Initiative PA Request Form if the member is prescribed other ehavioral health medications.
Se	ction I. Please complete for all requests for medications subject to the Pediatric Behavioral Health Medication Initiative for members < 18 years of age.
ŀ	s the member currently in an acute care setting?
	<ul><li>☐ Yes (Inpatient)</li><li>☐ Yes (Community Based Acute Treatment)</li><li>☐ Yes (Partial Hospitalization)</li><li>☐ No</li></ul>
F	or members who are in an acute care setting, please document the outpatient prescriber after discharge.
	Prescriber name Contact information

Has the member b	peen hospitalized for a psychiatric cor	ndition within the past three mo	onths?
☐ Yes. Please	e document dates of hospitalization w	rithin the past three months.	
<del></del>	imen, is the member considered to b	e a severe risk of harm to self	or others?
☐ Yes. Please	e provide details.		□ No
For regimens inclu	uding an antipsychotic, are appropriat movement disorder, cardiovascular,		oring being conducted (e.g.,
☐ Yes ☐ No. PI	lease explain.		
	sent from a parent or legal guardian bescriber specialty below.	een obtained?* 🗌 Yes 🔲 No	o 
Psychiatry	☐ Neurology ☐ Other		
	consult details (if the prescriber subm	tting the request is not a spec	ialist)
Name(s) of	the specialist(s)	Date(s) of last visit or consu	ılt
Contact info	ormation		
•	titioners (e.g., nurse practitioners, ph g physician, if applicable.	ysician assistants), please pro	vide the name and specialty
	member custody status. ardian	Families (DCF)	
	member placement status. Parent/Guardian	Residential Treatment Facility	
Uncertain [	Other		
DCF De	agency involvement. epartment of Mental Health (DMH)	Department of Developmenta	ll Services (DDS)
<del></del> .	t of Youth Services (DYS) nily currently receiving appropriate ps	vehotheraneutic and/or comm	unity hased services for the
targeted clinical m	ental health related concerns (e.g., A		
	nterventions, specialized placement)? e document details of interventions be	alow if applicable	
Tes. Flease	- document details of interventions by	ыом, ії арріісаві <del>с</del> .	
Psychiatric care pr	rovided is coordinated with other psyc	chotherapeutic and community	v based services ☐ Yes ☐ No
•	onsent form available on the MassHealth PB	•	
	v/info-details/pediatric-behavioral-health-me		
Section II. Moo	d Stabilizer Polypharmacy. Com	nolete this section for all r	nembers < 18 years of
	if request will result in prescrip	•	•
days	within a 90-day period (agents	considered to be used on	ly for seizure diagnoses
are r	not included).		
Please document	complete treatment plan (include all r	nood stabilizing agents).	
Mood stabilize	r name/dose/frequency	Indication	

Mood stabilizer name/dose/frequency	Indication
Mood stabilizer name/dose/frequency	Indication
Mood stabilizer name/dose/frequency	Indication
5. Other(s)	
. ,	ug name, dates/duration of use, and outcome) with mood
stabilizers were tried before prescribing polypharm	nacy with three or more mood stabilizers in this member.*
Please document the treatment plans for medication	on regimen simplification (e.g., dose consolidation, frequency
reduction) or medical necessity for continuation of	
*Attach a letter with additional information regarding	ng medication trials as applicable.
Section III. Mood Stabilizer Request for Me	mbers < six years of age (agents considered to be
used only for seizure diagnoses	•
indication(s) or ICD-10 code(s), if applicable, for the	e all mood stabilizer agents with dose/frequency/duration and requested medication(s)).
	1 (7)
Please document any previous medication trial(s).	Include the drug name, dates/duration of use, and outcome.*
Please document clinical rationale for use of a mod	od stabilizer for this member < six years of age.
*Attach a letter with additional information regarding	g medication trials as applicable.
• • • • • • • • • • • • • • • • • • •	cations. Complete this section for all members < 18 It in prescriptions of four or more behavioral health
medications within a 45-day per	iod. For a complete list of all behavioral health
	MassHealth Pediatric Behavioral Health Medication be used only for seizure diagnoses are not included)
	e all behavioral health agents and indication(s) or ICD-10
code(s), if applicable, for each medication(s)).	
Medication name/dose/frequency	Indication
Medication name/dose/frequency	Indication
Medication name/dose/frequency	Indication
	illuication -
Medication name/dose/frequency	Indication
<ul><li>4. Medication name/dose/frequency</li><li>5. Medication name/dose/frequency</li></ul>	
	Indication

7. Other(s)
Please document monotherapy trials (include drug name, dates/duration of use, and outcome) tried before prescribing a polypharmacy regimen for this member.*
Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen
*Attach a letter with additional information regarding medication trials as applicable.
The state of the s

Please continue to next page and complete Prescriber and Provider Information section.

## **Prior Authorization Request Prescriber and Provider Information**

Prescriber Information			
Last name*	First name*		мі
NPI*	Individual MH Provid	der ID	
DEA No.	Office Contact Name		
Address	City	State	Zip
Email address			
Telephone No.*  * Required	Fax No.*		
Please also complete for professionally ad	Iministered medication	ons, if applicabl	e.
Start date	End date	_	
Servicing prescriber/facility name		☐ Same as	prescribing provider
Servicing provider/facility address			
Servicing provider NPI/tax ID No.			
Name of billing provider			
Billing provider NPI No.			
Is this a request for recertification?   Yes   No	0		
CPT code No. of visits	J code	No. of u	units
Prescribing provider's attestation, signature I certify under the pains and penalties of perjury information section of this form. Any attached stall certify that the medical necessity information (particularly complete, to the best of my knowledge. I understand prosecution for any falsification, omission, or confidence in the provider's signature.	that I am the prescribing atement on my letterhea per 130 CMR 450.204) o stand that I may be subje ncealment of any materia	d has been review n this form is true, ct to civil penalties al fact contained h	ved and signed by me. , accurate, and s or criminal
		_	
Printed name of prescribing provider	n accounted or it can be	Date L	lly using DosuGian
(The form can either be signed by hand and the Adobe Sign. For electronic signatures, the signed signature is not an acceptable form of an electronic signature.)	er can upload a picture o	•	